Data completeness
3/8 — Basic
GASTROCROM by UCB Pharma is clinical pharmacology in vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Approved for the management of patients with mastocytosis.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GASTROCROM (cromolyn sodium) is an oral small-molecule mast cell stabilizer that inhibits the release of histamine and leukotrienes from sensitized mast cells. It is indicated for the management of patients with mastocytosis, a rare disorder characterized by abnormal mast cell proliferation. The drug has poor oral bioavailability (<1% absorbed), with the remainder excreted in feces.
$0.663MPart D
Pre-LaunchPre-launch status with minimal current market activity suggests early-stage team building and commercial infrastructure development opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Cromolyn sodium acts by inhibiting the release of histamine and leukotrienes (SRS-A) from the mast cell. Cromolyn sodium has no intrinsic…
Indications (1)
Worked on GASTROCROM at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.